Law360, New York (July 31, 2008, 12:00 AM ET) -- The U.S. Food and Drug Administration has warned Baxter Healthcare Corp. over a promotion of one of its hemophilia drugs that the agency says overstates the coagulant's safety and efficacy.
The company's "clinical thank you e-mail" misbrands FEIBA VH — a drug containing freeze-dried sterile human plasma that helps to limit spontaneous or surgical bleeding in patents with hemophilia — and violates the U.S. Food, Drug and Cosmetic Act, according to a letter posted to the agency's Web site Wednesday.
"By promoting misleading safety and efficacy...
FDA Warns Baxter On Hemophilia Drug Promotion
To view the full article, take a free trial now.
